Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active RA. A Multicenter Post-Marketing Observational Study in Routine Clinical Use.

Trial Profile

Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active RA. A Multicenter Post-Marketing Observational Study in Routine Clinical Use.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms FALLA
  • Sponsors Abbott Laboratories

Most Recent Events

  • 30 Dec 2011 Actual patient number changed from 84 to 82 as reported by ClinicalTrials.gov.
  • 21 Mar 2011 Actual initiation date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
  • 21 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top